Treatment of mild and moderate type-2 diabetes: open prospective trial with Hintonia latiflora extract

European Journal of Medical Research

Marie Hladikova²  Marta Korecova¹ 

[1] Head of Diabetes Department, IDF President, Rc: 425201/734, Vel’komoravská 2, Trencin, SK 91101, Slovak Republic;Department for Medical Informatics, 2nd Medical Faculty of Charles University of Prague, V Úvalu 84, Prague 5 CZ-15006, Czech Republic

关键词: Blood lipids;    Liver values;    Blood glucose;    HbA_1c;    Type 2 diabetes;    Hintonia latiflora;   

Others  :  817507
DOI  :  10.1186/2047-783X-19-16

 received in 2013-11-28, accepted in 2014-03-05,  发布年份 2014

【 摘 要 】

Background

Extracts from the bark of Hintonia latiflora are used as dietetic measures to support the regulation of glucose metabolism and the stabilization of blood glucose values.

Methods

A dry concentrated extract from the bark of Hintonia latiflora in capsule form was tested in an open, prospective clinical study in 41 dietetically stabilized subjects with type 2 diabetes. The effects on parameters of blood glucose control were documented over a period of six months.

Results

Fasting and postprandial glucose and the HbA_1c value declined significantly. In the case of HbA_1c, this meant a reduction of the absolute value from 7.49 ± 0.72% to 6.82 ± 0.67% (from 58.4 to 51.0 mmol/mol Hb; intention to treat (ITT) population). Furthermore, cholesterol and triglycerides were slightly reduced and no negative effect on other laboratory parameters and no change of the liver values were observed. Tolerance was very good. In particular, no side effects and no hypoglycemic episodes or worsening of diabetic symptoms occurred.

Conclusions

The study confirms the positive effect of extracts from the bark of Hintonia latiflora on blood glucose values suggesting a potential benefit in the management of glucose metabolism in cases of type 2 diabetes.

Trial registration

Reg.-No. ISRCTN83308122

【 授权许可】

   
2014 Korecova and Hladikova; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bastien M: Recherches sur les Copalchi, drogues hypoglycemiantes et en particulier sur le Coutarea latiflora D.C. (Rubiacee). Université de Paris; 1961. [PhD Dissertation]
• [2]Kaiser H, Geyer H: Zur Pharmakologie der Rinde von Coutarea latiflora D.C. Arch Pharm 1955, 288:595-608.
• [3]Paris R, Bastien M: A propos de l’action hypoglycémicante de deux drogues dénommées “Copalchi”: Coutarea latiflora (Rubiacées) et Croton niveus (Euphorbiacées). Ann Pharm Fr 1960, 18:205-219.
• [4]Pinto A, Capasso A, Sorrentino L: Experimental animal studies on the hypoglycemic effects of a Copalchi extract. Arzneimittelforschung/Drug Res 1997, 47:829-833.
• [5]Slijepcevic N, Kraus L: The diabetic mouse as an experimental model for measuring the blood-glucose lowering effects of plant extracts and insulin preparations. Acta Therap 1997, 23:47-58.
• [6]Guerrero-Analco J, Medina-Campos O, Brindis F, Bye R, Pedraza-Chaverri J, Navarrete A, Mata R: Antidiabetic properties of selected Mexican copalchis of the Rubiaceae family. Phytochemistry 2007, 68:2087-2095.
• [7]Guerrero-Analco JA, Hersch-Martinez P, Pedraza-Chaverri J, Navarrete A, Mata R: Antihyperglycemic effect of constituents from Hintonia standleyana in streptozotocin-induced diabetic rats. Planta Med 2005, 71:1099-1105.
• [8]Korec R, Sensch KH, Zoukas T: Effects of the neoflavonoid coutareagenin, one of the antidiabetic active substances of Hintonia latiflora, on streptozotocin-induced diabetes mellitus in rats. Arzneimittelforsch/Drug Res 2000, 50:122-128.
• [9]Kuhr R: Orale Diabetestherapie mit einem Euphorbiazeenextrakt. Landarzt 1953, 29:542-549.
• [10]Vida F: Erfahrungsbericht mit dem peroralen Antidiabetikum Sucontral. Med Welt 1951, 20:1623-1624.
• [11]Winter B: Zur Behandlung des Diabetes mellitus. Hippokrates 1951, 22:249-250.
• [12]Machens R: Zwei Fälle spontaner Regression des Diabetes mellitus Typ 2 nach Behandlung mit einem Phytotherapeutikum. Erfahrungsheilkunde 1991, 40(6):433-436.
• [13]Machens R: Ein Langzeitversuch mit Copalchi-Fluidextrakt, einem pflanzlichen Antidiabetikum. Erfahrungsheilkunde 1992, 41(6):416-420.
• [14]Korecova M, Hladikova M, Korec R: Hintonia latiflora bei Typ-2-Diabetes. Klinische Langzeitstudie. Z Phytother 2006, 27:272-278.
• [15]Bretzel RG, Voigt K, Schatz H: The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1998, 106:369-372.
• [16]Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
• [17]Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bampoint S, de Galan BE, Joshi R, Travert F, Advance Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
• [18]Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
• [19]Cefalu WT: Glycemic targets and cardiovascular disease. N Engl J Med 2008, 358:2633-2635.
• [20]Hoogwerf BJ: Action to Control Cardiovascular Risk in Diabetes Study G: Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med 2008, 75:729-737.
• [21]Del Prato S, Erkelens DW, Leutenegger M: Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol 2003, 40:20-27.
• [22]Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA: Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab 2002, 15:152-159.
• [23]Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jimenez F, Hardin PA, Konkoy CS, Tan MH: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003, 25:1074-1095.
• [24]United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88.
• [25]Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Look Ahead Research Group, et al.: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.